Spots Global Cancer Trial Database for Venetoclax After TKI to Target Persisting Stem Cells in CML
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Venetoclax After TKI to Target Persisting Stem Cells in CML
Official Title: Venetoclax After TKI to Target Persisting Stem Cells in CML
Study ID: NCT05701215
Conditions
Interventions
Study Description
Brief Summary: There is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug. The study will provide unprecedented biological insights on the effects of venetoclax in controlling minimal residual stem cell disease induced by long-term prior TKI therapy. If the study would be positive, the findings could become practice changing for patients in deep molecular remission under TKI and willing to tolerate a temporary additional treatment.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Uniklinik der RWTH Aachen, Aachen, , Germany
Universitätsklinikum Jena, Jena, , Germany
Contact Details
Name: Thomas Ernst, Prof. Dr.
Affiliation: University Hospital Jena
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
